- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Lobe Sciences Ltd (2): Lobe Sciences settles $1.37M in mgmt, director fees | 3 | Stockwatch | ||
| Di | Lobe Sciences Ltd.: Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares | 219 | ACCESS Newswire | Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholdersThe Canadian Securities Exchange has... ► Artikel lesen | |
| 02.06. | Lobe Sciences Ltd.: Lobe Sciences Announces Proposed Shares for Debt Transaction | 365 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen | |
| 07.05. | Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York | 513 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential... ► Artikel lesen | |
| 06.05. | Lobe Sciences Ltd.: Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress | 262 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen | |
| 24.04. | Lobe Sciences Ltd (2): Lobe Sciences cheers U.S. order for novel treatments | 4 | Stockwatch | ||
| 23.04. | Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders | 241 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing... ► Artikel lesen | |
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 21.04. | Lobe Sciences Ltd (2): Lobe Sciences hires Massive Intelligence for IR | 1 | Stockwatch | ||
| 21.04. | Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services | 298 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 20.04. | Lobe Sciences Ltd (2): Lobe Sciences closes $950,000 private placement | 2 | Stockwatch | ||
| 20.04. | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update | 282 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 13.04. | Lobe Sciences launches non-brokered private placement of 14.62M shares at $0.065 | 2 | Seeking Alpha | ||
| 11.04. | Lobe Sciences Ltd (2): Lobe Sciences arranges $950,000 private placement | 2 | Stockwatch | ||
| 11.04. | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | 658 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 25.03. | Lobe Sciences Ltd. meldet verbesserte Finanzlage und gibt strategisches Update bekannt | 408 | IR-WORLD | - Verbindlichkeiten um 81 % reduziert, von 2,35 Mio. $ auf 0,44 Mio. $
- Barmittel um mehr als das 24-Fache gestiegen, von 0,24 Mio. $ auf 5,99 Mio. $
... ► Artikel lesen | |
| 25.03. | Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update | 301 | ACCESS Newswire | Liabilities reduced 81%, from $2.35M to $0.44MCash increased more than 24x, from $0.24M to $5.99MNet working capital improved by $6.1M, from ($2.01M) to $4.05MOutstanding warrants reduced by ~70%, from... ► Artikel lesen | |
| 09.03. | Lobe Sciences names Mirza Rahimani as CFO; succeeds Yong Yao | 1 | Seeking Alpha | ||
| 09.03. | Lobe Sciences Ltd.: Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer | 441 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with... ► Artikel lesen | |
| 05.03. | Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences | 238 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British... ► Artikel lesen | |
| 03.02. | Lobe Sciences Ltd (2): Lobe Sciences' Nov. 30 cash at $5.99-million | 1 | Stockwatch |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,231 | +0,87 % | Biotech- und Life-Science-Boom: Evotec, BioNxt Solutions und Merck - wo lohnt sich ein Investment? | Die Life-Science- und Pharma-Branche erlebt einen strukturellen Wandel. Nicht mehr einzelne Blockbuster-Wirkstoffe, sondern Plattformtechnologien, Patentportfolios und strategische Deals treiben die... ► Artikel lesen | |
| ATAIBECKLEY | 3,380 | +3,05 % | H.C. Wainwright reiterates Buy on Atai stock, $25 target | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Appointment of Davidson & Company as Its New Auditor | Toronto, Ontario--(Newsfile Corp. - May 22, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), is pleased to announce the appointment of Davidson... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,020 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Change of Directors | Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes... ► Artikel lesen | |
| CYBIN | 3,555 | +1,43 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| REVIVE THERAPEUTICS | 0,012 | 0,00 % | XFRA 31R: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILREVIVE THERAPEUTICS... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics treibt die Erweiterung der pharmazeutischen Produktion | DJ PTA-News: Rapid Dose Therapeutics Inc.: Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) treibt die Erweiterung der pharmazeutischen Produktion - durch Modernisierungen am Standort Burlington... ► Artikel lesen | |
| TANGO THERAPEUTICS | 29,820 | 0,00 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,080 | 0,00 % | Summit Therapeutics withdraws proposed securities offering citing market conditions | ||
| PROPANC BIOPHARMA | 2,430 | 0,00 % | Morning Market Movers: Galaxy Payroll, Propanc Biopharma, Big Tree Cloud, VS MEDIA See Big Swings | REDWOOD SHORES (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 40,340 | -0,05 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| CG ONCOLOGY | 57,64 | 0,00 % | CG Oncology, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,150 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,240 | 0,00 % | Relay Therapeutics, Inc. - 8-K, Current Report | ||
| PARABILIS MEDICINES | 30,310 | 0,00 % | HBM Healthcare Investments AG: HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines
11.06.2026 / 07:00... ► Artikel lesen |
LOBE SCIENCES LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,059 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.